当前位置:首页 >财报库 > 报告详情

百时美施贵宝Bristol Myers Squibb(BMY)2025年第三季度财报(10-Q)「NYSE」(英文版)(60页).pdf

上传人: 1****1 编号:987239 2025-12-09 60页 563.20KB

下载:

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549_FORM 10-Q_ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30,2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 193

2、4For the transition period from _ to _Commission File Number 001-01136_BRISTOL-MYERS SQUIBB COMPANY(Exact name of registrant as specified in its charter)_Delaware 22-0790350(State or other jurisdiction ofincorporation or organization)(I.R.S EmployerIdentification No.)Route 206&Province Line Road,Pri

3、nceton,New Jersey 08543(Address of principal executive offices)(Zip Code)(609)252-4621(Registrants telephone number,including area code)_(Former name,former address and former fiscal year,if changed since last report)Securities registered pursuant to Section 12(b)of the Act:Title of each classTradin

4、g Symbol(s)Name of each exchange on which registeredCommon Stock,$0.10 Par ValueBMYNew York Stock Exchange1.750%Notes due 2035BMY35New York Stock ExchangeCelgene Contingent Value RightsCELG RTNew York Stock ExchangeIndicate by check mark whether the registrant(1)has filed all reports required to be

5、filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 duringthe preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to the filing requirements for thepast 90 days.Yes No Indicate by check mark whether the registran

6、t has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that the registrant was required to submit suchfiles).Yes No Indicate by check mark whether the

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,以下是Bristol-Myers Squibb公司(BMS)2025年第三季度报告的简要概括: - **季度收入**:净产品销售额为11.85亿美元,总营收为12.22亿美元。 - **盈利情况**:净收入为2.2亿美元,每股收益为1.08美元。 - **研发投入**:研发支出为2.53亿美元。 - **联盟与合作**:与BioNTech和SystImmune等公司合作开发新药。 - **收购**:收购了Orbital Therapeutics、2seventy bio、Karuna、RayzeBio和Mirati等公司。 - **剥离**:剥离了糖尿病业务和其他成熟产品。 - **财务状况**:截至2025年10月23日,公司流通股为20.36亿股。 - **现金流**:经营活动产生的现金流量为12.18亿美元,投资活动为负2.674亿美元,融资活动为负4.319亿美元。
**业绩大揭秘** **财报亮点解析** **BMS战略布局探秘**
客服
商务合作
小程序
服务号
折叠